SEQUANA MEDICAL N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 EUR | -1.06% |
|
-1.75% | -65.00% |
Presentation Operator MessageOperator (Operator)Hello, and welcome to Heart Failure Drug Devel...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Sequana Medical N.V. is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump is a fully-implanted, wireless device that automatically pumps fluid from the abdomen into the bladder, where it is removed naturally through urination. The alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and has been granted breakthrough device designation by the US FDA with a North American pivotal study underway. DSR is a novel approach to manage sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity. The alfapump DSR® combines DSR therapy with the proven alfapump platform and is in clinical development as potential treatment for decompensated heart failure patients.
Calendar
2024-05-22
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.4
EUR
Average target price
5.967
EUR
Spread / Average Target
+326.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -65.00% | 54.37M | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| +9.45% | 41.31B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B |
- Stock Market
- Equities
- SEQUA Stock
- News Sequana Medical N.V.
- Transcript : Sequana Medical NV - Special Call
